/
/
IMW: Iberdomide Demonstrates Ability to Overcome Resistance to Common Myeloma Therapies
IMW: Iberdomide Demonstrates Ability to Overcome Resistance to Common Myeloma Therapies image
IMW: Iberdomide Demonstrates Ability to Overcome Resistance to Common Myeloma Therapies
Posted Oct 07, 2021

A new drug called iberdomide when combined with daratumumab, bortezomib or carfilzomib is showing positive effects with fewer side effects than its predecessor drugs lenalidomide and pomalidomide, according to research presented at the IMW meeting in Vienna by Sagar Lonial, MD, FACP of Emory University. 

Iberdomide is a new oral drug called a CELMoD. While it shares similarities with well known immunomodulator drugs lenalidomide and pomalidomide, it is a completely unique type of drug. Iberdomide binds to cereblon (CRBN) to help degrade target proteins Ikaros and Aiolos. Iberdomide both stimulates the immune system and has direct anti-myeloma killing abilities. Importantly, it also works in patients who are resistant to lenalidomide and pomalidomide. 

Many patients who entered the study were already resistant to bortezomib or immunomodulators. Interestingly, these patients still responded to 

The patients were split into three study groups: Iberdomide/daratumumab/dex, Iberdomide/Velcade/dex and Iberdomide/Kyprolis/dex. One of the primary goals of the study was to determine the best dose when iberdomide was combined with the other myeloma drugs. 

Outcomes of iberdomide in the various combinations were as follows:  

  IberDd IberVd IberKd
Overall response Rate 45.9% 56% 50%

Stringent CR

2.7%   12.5%
Complete Response 5.4% 4%  
Very Good Partial Response 16.2% 24% 25%
Partial Response 21.6% 28% 12.5%
Minimal Response 8.1% 8%  
Stable Disease 35.1% 24% 37.5%
Progressive Disease 10.8% 8% 12.5%

 

The side effect profile was very reasonable, with very few severe reactions of fatigue, rash and gastrointestinal disorders. These side effects are quite common for patients taking Revlimid or Pomalyst. The recommended dose determined as part of the study for iberdomide with daratumumab is 1.6 mg. The dose to be used with a proteasome inhibitor remains to be determined. 

Dr. Lonial concluded his presentation by stating that iberdomide was promising for patients in these combinations even for patients who were refractory to commonly used drugs like proteasome inhibitors, immunomodulatory drugs and CD-38 antibodies. 

Myeloma patients are always happy to see more effective drugs with a lower side effect profile in development. We look forward to iberdomide running through Phase III studies and will follow the progression.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811